Ocera Therapeutics Inc news

   Watch this stock
Showing stories 1 - 10 of about 78   

Articles published

OCRX 4.50 -0.22 (-4.66%)
price chart
Ocera Therapeutics Finally Ready To Reward Investors
Furthermore, to bluntly state the obvious, Ocera has had a rough 2014. Investors unfamiliar with the company would probably look at the stock chart and move on to the next assuming that something catastrophic had occurred to warrant such a steep price ...
Ocera Therapeutics to Present at 35th Annual Cowen and Company Health ...
Ocera Therapeutics, Inc. OCRX, -3.26% a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that company management will be presenting at the 35th Annual Cowen and Company Health Care ...
Ocera Therapeutics Well-Capitalized After The Merger
Ocera Therapeutics (NASDAQ:OCRX) announced the closing of a merger with Tranzyme on July 15. Immediately following the closing of the merger, certain of the Ocera investors invested approximately $20 million in the company through a private ...
Ocera sinks on mixed clinical trial results (OCRX)
Thinly-traded nano cap Ocera Therapeutics (NASDAQ:OCRX) is off 17% premarket on higher-than-normal volume in response to its report of top-line results from a 38-patient Phase 2a study evaluating its lead product candidate OCR-002 (ornithine ...
Ocera Therapeutics (OCRX) Reports OCR-002 Phase 2a Missed Primary Endpoint  StreetInsider.com
Ocera Announces Preliminary Topline Results From Phase 2a Investigator ...  GlobeNewswire (press release)
Ocera Therapeutics: A Potential Multibagger Biopharmaceutical Company
Ocera Therapeutics [Nasdaq: (NASDAQ:OCRX)] announced the initiation of its phase 2b double blind, controlled, randomized clinical trial in early January 2014.
Related articles »  
Ocera Therapeutics, Inc. Short Interest Disclosure
Ocera Therapeutics, Inc. (NASDAQ:OCRX) reported a shortfall of 2,369 shares or 0.5% in the short interest. The remaining shorts are 4.3% of the total floated shares.
Coverage Reiterated: Acadia (ACAD), Alibaba Group (BABA), Ocera ...  Wall Street Pit
Ocera Therapeutics Inc.: Ocera Reports Fourth Quarter and Full Year 2014 ...  The Wall Street Transcript
Ocera Therapeutics to Announce Fourth Quarter and Full Year 2014 Financial ...
PALO ALTO, Calif., March 2, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that it will release its fourth quarter and ...
Ocera Therapeutics, Inc. Files SEC Form SC 13G, Statement of Acquisition of ...
By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C. , by NewsRx journalists, a U.S.
Ocera Therapeutics Announces Completion of Merger With Tranzyme
SAN DIEGO, July 15, 2013 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. ("Ocera"), a clinical stage biopharmaceutical company developing novel therapeutics for orphan liver diseases, and Tranzyme, Inc. (Nasdaq:TZYM) ("Tranzyme") today announced ...
Related articles »  
Ocera Therapeutics Promotes Michael Byrnes to Chief Financial Officer
PALO ALTO, Calif., Dec. 3, 2014 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical-stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced the appointment of Michael Byrnes as ...
Related articles »